Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina.
IUBMB Life. 2012 Jan;64(1):18-26. doi: 10.1002/iub.574. Epub 2011 Nov 17.
The protein kinase C (PKC) family of serine/threonine kinases has been intensively studied in cancer since their discovery as major receptors for the tumor-promoting phorbol esters. The contribution of each individual PKC isozyme to malignant transformation is only partially understood, but it is clear that each PKC plays different role in cancer progression. PKC deregulation is a common phenomenon observed in breast cancer, and PKC expression and localization are usually dynamically regulated during mammary gland differentiation and involution. In fact, the overexpression of several PKCs has been reported in malignant human breast tissue and breast cancer cell lines. In this review, we summarize the knowledge available on the specific roles of PKC isoforms in the development, progression, and metastatic dissemination of mammary cancer. We also discuss the role of PKC isoforms as therapeutic targets, and their potential as markers for prognosis or treatment response.
蛋白激酶 C（PKC）家族是丝氨酸/苏氨酸激酶，自发现其作为肿瘤促进佛波酯的主要受体以来，一直在癌症中进行了深入研究。尽管每个 PKC 同工酶对恶性转化的贡献仅部分了解，但很明显，每个 PKC 在癌症进展中都发挥着不同的作用。PKC 失调是乳腺癌中观察到的常见现象，PKC 的表达和定位通常在乳腺分化和退化过程中动态调节。事实上，已经在恶性人乳腺组织和乳腺癌细胞系中报道了几种 PKCs 的过表达。在这篇综述中，我们总结了 PKC 同工型在乳腺癌发展、进展和转移传播中的特定作用的现有知识。我们还讨论了 PKC 同工型作为治疗靶点的作用，以及它们作为预后或治疗反应标志物的潜力。
